Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. (Q35902523)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Oncolytic viruses for the treatment of cancer: current strategies and clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Stefan J Ries

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

1 reference

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

759-768

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

Replication-selective viruses for cancer therapy

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

1 reference

7 January 2021

Principles of tumor immunosurveillance and implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

RNA viruses as virotherapy agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Reovirus as a novel oncolytic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Vectors based on autonomous parvoviruses: novel tools to treat cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Antineoplasic activity of parvoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Oncolytic herpes simplex virus vectors for cancer virotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Intergeneric poliovirus recombinants for the treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Viral transactivating proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

E1A signaling to p53 involves the p19(ARF) tumor suppressor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

ONYX-015 selectivity and the p14ARF pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Telomerase-dependent oncolytic adenovirus for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Gene therapy using tissue-specific replication competent HSV.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Ligand-directed targeting of genes to the site of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Systemic tumor targeting and killing by Sindbis viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

The complement response against an oncolytic virus is species-specific in its activation pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903221-0

7 January 2021

10.1016/S1359-6446(04)03221-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15450242%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference